title: Reply: To PMID 22846802.
authors.affiliation: *Centre for Vision and Vascular Sciences, Queen University, Belfast, Northern Ireland, United Kingdom †Department of Ophthalmology, Grampian University Hospital-NHS Trust, Aberdeen, Scotland, United Kingdom ‡Department of Medical Statistics, Section of Population Health, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
authors.forename: Noemi
authors.initials: N
authors.lastname: Lois
authors.forename: Vikki
authors.initials: V
authors.lastname: McBain
authors.forename: Ehab
authors.initials: E
authors.lastname: Abdelkader
authors.forename: Neil W
authors.initials: NW
authors.lastname: Scott
authors.forename: Reena
authors.initials: R
authors.lastname: Kumari
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D057135:Wet Macular Degeneration / Q000175:diagnosis*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized